Calyxo vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 36)
Calyxo logo

Calyxo

EmergingHealthcare

Urology Medical Devices — Kidney Stone Retrieval

Calyxo is a urology medical device company developing CVAC, a vacuum-assisted catheter for kidney stone fragment retrieval; raised $80M Series C in 2023;

AI VisibilityBeta
Overall Score
D36
Category Rank
#519 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
38
Gemini
34

About

Calyxo is a medical device company founded in 2017 and headquartered in Pleasanton, California, focused on improving outcomes in kidney stone treatment. The company's lead product is the CVAC System (Calyxo Vacuum-Assisted Catheter), an FDA-cleared ureteroscopy tool that uses suction to vacuum out kidney stone fragments during a single minimally invasive procedure. Traditional stone removal with a basket retrieval device requires multiple passes and often leaves residual fragments — a problem Calyxo's system addresses by continuously aspirating debris as the laser breaks up stones, achieving substantially higher stone-free rates in a single operating room session.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

36
Overall Score
90
#519
Category Rank
#2
79
AI Consensus
83
stable
Trend
stable
40
ChatGPT
92
38
Perplexity
93
34
Gemini
89
33
Claude
96
32
Grok
95

Key Details

Category
Urology Medical Devices — Kidney Stone Retrieval
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.